Celldex Announces Proposed Public Offering of Common Stock

Biotechnology firm seeks to raise funds for commercial launch and pipeline development

Apr. 1, 2026 at 8:42pm

Got story updates? Submit your updates here. ›

Celldex Therapeutics, Inc., a clinical-stage biotechnology company, has announced the launch of an underwritten public offering to sell shares of its common stock. The company plans to use the net proceeds to fund the commercial launch of its lead drug candidate barzolvolimab, continue clinical development of its pipeline, and support general corporate purposes.

Why it matters

The proposed public offering is a significant milestone for Celldex as it seeks to transition from a clinical-stage to a commercial-stage biopharmaceutical company. The funds raised will be crucial for the successful launch of barzolvolimab and advancing the company's broader pipeline of antibody-based therapeutics targeting severe inflammatory, allergic, and autoimmune diseases.

The details

Celldex has commenced the underwritten public offering to sell shares of its common stock. The company also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares offered. Celldex intends to use the net proceeds to fund the commercial readiness and launch of barzolvolimab for the treatment of chronic spontaneous urticaria (CSU) in the United States, continue the clinical and preclinical development of its product candidates, grow its bispecific antibody platform, and support general corporate purposes.

  • Celldex filed a shelf registration statement on Form S-3 with the SEC on November 3, 2023, which became automatically effective.
  • The company announced the proposed public offering on April 1, 2026.

The players

Celldex Therapeutics, Inc.

A clinical-stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients.

Leerink Partners

One of the joint bookrunning managers for the proposed public offering.

TD Cowen

The other joint bookrunning manager for the proposed public offering.

Got photos? Submit your photos here. ›

What’s next

The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

The takeaway

Celldex's proposed public offering is a critical step in the company's evolution, as it seeks to transition from a clinical-stage to a commercial-stage biopharmaceutical firm and advance its pipeline of innovative antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases.